Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

NCT02263898 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped closed without enrollment

Conditions

Recurrent Melanoma
Stage IV Melanoma

Interventions

DRUG: Raf kinase inhibitor LGX818
DRUG: binimetinib
OTHER: laboratory biomarker analysis

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]